ZOETIS INC. Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 150,9 USD | +0,88% |
|
-0,70% | -23,55% |
| 23/04 | ZOETIS INC. : Barclays ontvangt een koopadvies | ZM |
| 23/04 | ZOETIS INC. : Jefferies & Co. is Neutraal gestemd over aandeel | ZM |
Vakgebied
- huisdieren (64,4%): katten en honden (94,9% van de netto-omzet) en paarden (5,1%);
- vee (34,5%): runderen (51,6% van de omzet), varkens (20,2%), pluimvee (17,1%), vissen (7,6%) en overige (3,5%);
- overige (1,1%).
De netto-omzet wordt per productfamilie uitgesplitst in parasiticiden (23%), vaccins (21,3%), dermatologische producten (16,4%), anti-infectiva (13,4%), medische voedingsadditieven (4,5%), diagnostische producten (4,4%) en overige (17%).
Eind 2022 heeft de groep wereldwijd 29 productievestigingen.
De Verenigde Staten zijn goed voor 53,4% van de netto-omzet.
Aantal werknemers: 14 100
Verkoop per activiteit
| USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
Parasiticides
22,8
%
| 1 860 | 23,0 % | 1 947 | 22,8 % | +4,68% |
Vaccines
20,7
%
| 1 718 | 21,3 % | 1 771 | 20,7 % | +3,08% |
Dermatology
16,7
%
| 1 329 | 16,4 % | 1 427 | 16,7 % | +7,37% |
Other Pharmaceuticals
15,0
%
| 1 043 | 12,9 % | 1 280 | 15,0 % | +22,72% |
Anti-infectives
12,4
%
| 1 081 | 13,4 % | 1 057 | 12,4 % | -2,22% |
Animal Health Diagnostics
4,4
%
| 353 | 4,4 % | 376 | 4,4 % | +6,52% |
Medicated Feed Additives
4,1
%
| 360 | 4,5 % | 354 | 4,1 % | -1,67% |
Other Non-pharmaceuticals
3,0
%
| 250 | 3,1 % | 254 | 3,0 % | +1,60% |
Contract Manufacturing and Human Health
0,9
%
| 86 | 1,1 % | 78 | 0,9 % | -9,30% |
Verkoop per regio
| USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
|---|---|---|---|---|---|
United States
53,3
%
| 4 313 | 53,4 % | 4 555 | 53,3 % | +5,61% |
Other Emerging Markets
9,2
%
| 758 | 9,4 % | 784 | 9,2 % | +3,43% |
Other Developed Markets
6,0
%
| 468 | 5,8 % | 512 | 6,0 % | +9,40% |
Brazil
4,6
%
| 330 | 4,1 % | 393 | 4,6 % | +19,09% |
Australia
3,8
%
| 289 | 3,6 % | 323 | 3,8 % | +11,76% |
China
3,7
%
| 382 | 4,7 % | 320 | 3,7 % | -16,23% |
United Kingdom
3,2
%
| 235 | 2,9 % | 277 | 3,2 % | +17,87% |
Canada
3,0
%
| 238 | 2,9 % | 255 | 3,0 % | +7,14% |
Germany
2,4
%
| 176 | 2,2 % | 202 | 2,4 % | +14,77% |
Mexico
1,9
%
| 136 | 1,7 % | 162 | 1,9 % | +19,12% |
Japan
1,8
%
| 173 | 2,1 % | 158 | 1,8 % | -8,67% |
France
1,7
%
| 126 | 1,6 % | 142 | 1,7 % | +12,70% |
Chile
1,6
%
| 141 | 1,7 % | 140 | 1,6 % | -0,71% |
Spain
1,4
%
| 118 | 1,5 % | 122 | 1,4 % | +3,39% |
Italy
1,4
%
| 111 | 1,4 % | 121 | 1,4 % | +9,01% |
Global
0,9
%
| 86 | 1,1 % | 78 | 0,9 % | -9,30% |
Managers
| Managers | Titel | Leeftijd | Van |
|---|---|---|---|
Kristin Peck
CEO | Chief Executive Officer | 52 | 01-01-12 |
Wetteny Joseph
DFI | Director of Finance/CFO | 52 | 01-06-21 |
Mike McFarland
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-11 |
Robert Polzer
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-01-15 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 56 | 01-01-20 |
Steven Frank
IRC | Investor Relations Contact | - | 01-03-15 |
William Dorsey
PRN | Corporate Officer/Principal | - | - |
Ester Banque
PRN | Corporate Officer/Principal | - | 10-07-23 |
Abhay Nayak
PRN | Corporate Officer/Principal | - | - |
Roxanne Lagano
HRO | Human Resources Officer | 59 | 01-10-12 |
Besturend
| Besturend | Titel | Leeftijd | Van |
|---|---|---|---|
| Chairman | 71 | 01-01-13 | |
Louise Parent
BRD | Director/Board Member | 73 | 01-08-13 |
Robert Scully
BRD | Director/Board Member | 74 | 01-06-13 |
Kristin Peck
CEO | Chief Executive Officer | 52 | 01-01-12 |
Paul Bisaro
BRD | Director/Board Member | 63 | 01-05-15 |
Frank D'Amelio
BRD | Director/Board Member | 66 | 01-07-12 |
Sanjay Khosla
BRD | Director/Board Member | 71 | 01-06-13 |
Gregory Norden
BRD | Director/Board Member | 66 | 01-01-13 |
| Director/Board Member | 55 | 25-07-22 | |
Willie Reed
BRD | Director/Board Member | 69 | 04-03-14 |
Aandelenklasse
| Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
|---|---|---|---|---|---|
| Aandeel A | 1 | 500 471 090 | 455 877 565 ( 91,09 %) | 43 523 885 ( 8,697 %) | 91,09 % |
Bedrijfsgegevens
Bedrijven van de groep
| Naam | Categorie en sector |
|---|---|
Pharmaq AS
 Pharmaq AS Pharmaceuticals: MajorHealth Technology PHARMAQ AS operates as a veterinary pharmaceutical company. It provides health products to the global aquaculture industry. The company was founded on July 23, 2004 and is headquartered in Overhalla, Norway. |
Pharmaceuticals: Major
|
Zoetis India Ltd.
 Zoetis India Ltd. Pharmaceuticals: MajorHealth Technology Founded in 2007, Zoetis India Ltd. is a subsidiary of Zoetis, Inc. that manufactures vaccines and injectable biologic medicines. The private company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Zoetis Treasury Center BV
| |
Zoetis Belgium SA
 Zoetis Belgium SA BiotechnologyHealth Technology Part of Zoetis, Inc., Zoetis Belgium SA is a Belgian company that manufactures animal vaccines and prescription medicines. The private company is based in Louvain-La-Neuve, Belgium. |
Biotechnology
|
Zoetis Singapore Pte Ltd.
| |
Zoetis Vietnam LLC
 Zoetis Vietnam LLC Pharmaceuticals: MajorHealth Technology Zoetis Vietnam LLC engages in the distribution of medicine and vaccinations for pets and livestocks. The company was founded on August 16, 2013 and is headquartered in Ho Chi Minh City, Vietnam. |
Pharmaceuticals: Major
|
Zoetis Pharmaceutical Research Pvt Ltd.
| |
Zoetis Korea Ltd.
 Zoetis Korea Ltd. Pharmaceuticals: MajorHealth Technology Part of Zoetis, Inc., Zoetis Korea Ltd. is a South Korean company that manufactures veterinary medicinal preparations. The private company is located in South Korea. |
Pharmaceuticals: Major
|
Pharmaq Vietnam Co. Ltd.
|
Sector
Verkoop per activiteit
Verkoop per regio
Trading rating
Beleggingsrating
ESG Refinitiv
B+
Verkoop
Koop
Gemiddeld advies
Kopen
Aantal analisten
19
Laatste slotkoers
150,9
USD
Gemiddelde koersdoel
215,2
USD
Spread / Gemiddelde doel
+42,62%
Herzieningen van WPA
| Vaira. 1 jan. | Kapi. | |
|---|---|---|
| -23,55% | 68,34 mld. | |
| -10,67% | 6,64 mld. | |
| +16,00% | 3,41 mld. | |
| +0,14% | 3,21 mld. | |
| +2,53% | 1,46 mld. | |
| -14,67% | 1,38 mld. | |
| -2,44% | 1,25 mld. | |
| -27,57% | 1,21 mld. | |
| -12,86% | 1,13 mld. | |
| -2,99% | 1,03 mld. |
